Press centre

Venatorx Pharmaceuticals and GARDP partner to develop new antibiotic for hospital acquired infections with limited treatment options
29 Apr 2020

Venatorx Pharmaceuticals and GARDP partner to develop new antibiotic for hospital acquired infections with limited treatment options

GARDP and Venatorx Pharmaceuticals today announced a collaboration to accelerate the development of cefepime-taniborbactam, an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).

Read more

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.